雷 泮赛珠 单抗
单克 | |
---|---|
种类 | ? |
PCSK9 | |
其他 | RN317、PF‐05335810 |
ATC碼 |
|
识别 | |
CAS | 1407495-04-8 |
ChemSpider |
|
UNII | |
C6422H9922N1730O2012S54 | |
145,289.36 g·mol−1 |
参考 资料[编辑]
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 (PDF). WHO Drug Information. 2013, 27 (4) [2023-12-27]. (
原始 内容 存 档 (PDF)于2020-08-15). - ^ Ralpancizumab (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association..
- ^ Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, Garzone PD. A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy. Clinical and Translational Science. January 2017, 10 (1): 3–11. PMC 5351011
. PMID 27860267. doi:10.1111/cts.12430.
|